Key facts
- It has raised $14.2M; the latest was Early Stage VC ($14.2M) in Jan 2026.
- Notable investors include CAS Star, Legend Star, Gobi Partners.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Guoke Xinglian
- ·The full record, as it builds
Funding rounds
No funding rounds for Guoke Xinglian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Guoke Xinglian
Operator of biosynthetic human-derived active protein intended for therapeutic and immune health applications. The company specializes in innovative biomanufacturing of human homologous lactoferrin, incorporating advanced glycosylation modification processes, precision fermentation systems, scalable production workflows, and rigorous quality control protocols, enabling pharmaceutical companies, healthcare providers, and nutrition brands to deliver high-purity functional proteins that support antimicrobial defense, enhance immunity, promote cell growth and wound healing, and ensure consistent performance for clinical and consumer applications while meeting regulatory standards.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- castarfoods.com/
- Ownership
- Privately Held (backing)
Guoke Xinglian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Guoke Xinglian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Guoke Xinglian in its N-PORT filings yet. We sweep new filings monthly.